Viatris Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Viatris ha aumentado sus beneficios a una tasa media anual de 32.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 9.3% al año. La rentabilidad financiera de Viatris es de 0.3%, y sus márgenes netos son de 0.4%.

Información clave

32.8%

Tasa de crecimiento de los beneficios

22.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	9.3%
Rentabilidad financiera	0.3%
Margen neto	0.4%
Próxima actualización de resultados	09 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Viatris. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:VTRS Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	15,427	55	3,753	802
30 Sep 23	15,466	1,832	3,682	817
30 Jun 23	15,602	1,854	3,653	781
31 Mar 23	15,800	1,904	3,553	735
31 Dec 22	16,263	2,079	3,518	661
30 Sep 22	16,728	804	3,584	745
30 Jun 22	17,187	761	3,678	719
31 Mar 22	17,648	168	4,101	711
31 Dec 21	17,886	-1,269	4,245	668
30 Sep 21	17,168	-1,921	4,802	625
30 Jun 21	15,604	-2,047	4,382	603
31 Mar 21	13,757	-1,728	3,686	565
31 Dec 20	11,946	-670	2,686	550
30 Sep 20	11,514	266	2,445	486
30 Jun 20	11,504	271	2,427	487
31 Mar 20	11,624	63	2,503	492
31 Dec 19	11,501	17	2,503	519
30 Sep 19	11,387	48	2,445	519
30 Jun 19	11,288	34	2,452	532
31 Mar 19	11,245	240	2,378	568
31 Dec 18	11,434	353	2,397	586
30 Sep 18	11,594	546	2,303	622
30 Jun 18	11,719	457	2,385	648
31 Mar 18	11,873	717	2,435	663
31 Dec 17	11,908	696	2,564	666
30 Sep 17	11,937	869	2,357	655
30 Jun 17	12,007	661	2,356	665
31 Mar 17	11,605	533	2,300	663
31 Dec 16	11,077	480	2,351	698
30 Sep 16	10,300	257	2,150	691
30 Jun 16	9,938	806	2,019	688
31 Mar 16	9,749	805	1,973	687
31 Dec 15	9,429	848	1,924	652
30 Sep 15	9,021	842	1,885	645
30 Jun 15	8,410	913	1,767	628
31 Mar 15	7,876	870	1,616	599
31 Dec 14	7,720	929	1,499	564
30 Sep 14	7,445	920	1,474	544
30 Jun 14	7,129	580	1,398	499
31 Mar 14	6,993	633	1,326	470
31 Dec 13	6,909	624	1,338	456
30 Sep 13	6,823	605	1,294	439
30 Jun 13	6,858	658	1,291	430

Ingresos de calidad: VTRS tiene un gran one-off loss de $1.6B impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(0.4%) de VTRS son inferiores a los del año pasado (12.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lVTRS han crecido significativamente en un 32.8% al año.

Acelerando crecimiento: VTRS ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: VTRS tuvo un crecimiento negativo de los beneficios (-97.4%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-6.8%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de VTRS (0.3%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Viatris Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Price target decreased to US$12.55

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Viatris stock rises amid potential plans for €3B sale of European OTC assets

Take These Broken Wings And Learn To Fly Again Viatris

Viatris: 5% Dividend Yield Is A Threat For Investors

Independent Non-Executive Director recently sold US$100k worth of stock

Viatris: Products, Profitability And Pipeline - The Keys To Success

Upcoming dividend of US$0.12 per share

Consensus forecasts updated

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris declares $0.12 dividend

Viatris: A Spinoff To Own

Desglose de ingresos y gastos
Beta